Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768649 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of RBP-7000
A Phase 1 study of Schizophrenia, sponsored by Indivior.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02768649: Completed Phase 1 study of Schizophrenia, sponsored by Indivior.
NCT02768649 is a Phase 1 study of Schizophrenia that has completed, run by Indivior. The registered enrollment target is 45 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02768649, a Phase 1 study of Schizophrenia, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia
Primary Outcome
Adverse events, serious adverse events, and discontinuations due to AEs related to treatment.
Conditions Studied
Interventions
- DRUG risperidone
- DRUG RBP-7000
Study Locations (1)
New Jersey
- CRI Worldwide - Willingboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT02768649 record still lists
NCT02768649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which risperidone is the first listed.
NCT02768649 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02768649 about?
NCT02768649 is a clinical study titled "Single Ascending Dose Study of RBP-7000". The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia
What is the current status of trial NCT02768649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-04. Estimated completion is 2012-02.
What conditions does trial NCT02768649 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02768649?
The interventions under investigation include: risperidone (DRUG), RBP-7000 (DRUG).
Who is sponsoring clinical trial NCT02768649?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02768649 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02768649's enrollment target sits among peer trials
45 228th of 315 higher than 87 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia